REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- FRUTAROM
- GAZIT GLOBE
- HAREL
- ICL
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 13/03/2018 >View issuer details

2018.09.17 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2018.09.17 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2018.09.15 | 08:03 | Permanent Information Releases / General Company News

puce Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab) - HTML (w)

2018.09.15 | 08:03 | Permanent Information Releases / General Company News

puce Sanofi : Les résultats positifs de phase III concernant Dupixent® (dupilumab) - HTML (w)

2018.09.13 | 12:00 | Permanent Information Releases / General Company News

puce Sanofi to refocus two global business units - HTML (w)

2018.09.13 | 12:00 | Permanent Information Releases / General Company News

puce Sanofi recentre deux de ses entités commerciales globales - HTML (w)

2018.09.12 | 07:00 | Permanent Information Releases / General Company News

puce FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events - HTML (w)

2018.09.12 | 07:00 | Permanent Information Releases / General Company News

puce La FDA va examiner la demande supplémentaire de licence de produit biologique pour Praluent® (alirocumab), solution injectable, en tant que traitement potentiel dans la réduction d'événements cardi... - HTML (w)

2018.09.10 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2018.09.10 | 18:00 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2018.09.04 | 18:15 | Permanent Information Releases / General Company News

puce Sanofi reaches civil settlement with US SEC - HTML (w)

2018.09.04 | 18:15 | Permanent Information Releases / General Company News

puce Sanofi conclut un accord avec la « Securities and Exchange Commission » américaine - HTML (w)

2018.09.04 | 13:41 | Share Buybacks / Share redemption disclosures

puce Sanofi: Disclosure of trading in own shares - HTML (w)

2018.09.04 | 13:41 | Share Buybacks / Share redemption disclosures

puce Sanofi : Déclaration des transactions sur actions propres - HTML (w)

2018.09.03 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2564